UK Launches Clinical Trials to Investigate Puberty Blockers' Impact on Young People
In an effort to shed light on the impact of puberty blockers on young people with gender incongruence, two new clinical trials have been announced by researchers in the UK. The moves come amid controversy over the use of these medications for minors.
Originally developed to treat early onset puberty, puberty blockers are often prescribed off-label to children with gender dysphoria or incongruence. However, a 2024 review of NHS services found insufficient evidence on their effects on psychological wellbeing, cognitive development, and fertility. As a result, the NHS announced in 2023 that children receiving puberty blockers would no longer be offered routine treatment but could only access them through research studies.
The two new trials, part of the "Pathways" programme, aim to explore the impact of these medications among young people being treated by specialist NHS services. The first study, called Pathways Trial, will recruit 226 participants aged 10-15 and randomly assign them to start puberty blockers immediately or delay treatment for a year. Participants' health and development will be closely monitored over 24 months.
Meanwhile, the second study, Pathways Connect, will involve about 250 young people β including those receiving puberty blockers and those not β undergoing MRI brain imaging and cognitive tests. The trial is expected to run for at least four years, generating significant uncertainty around the outcomes.
Critics argue that these trials are coercive in nature, as participants will be forced to wait a year before accessing treatment. Chay Brown, health director of TransActual, described this practice as "distressing" and warned it may lead to negative consequences for young trans people in the UK.
Despite concerns, researchers believe new medications often require clinical trials to assess their safety and efficacy. Emily Simonoff, professor of child and adolescent psychiatry at King's College London, acknowledged that puberty blockers were not initially tested on minors but suggested a trial was necessary given the medication's limited history.
The trials' outcomes will shed light on the long-term effects of puberty blockers on young people with gender incongruence. However, many questions remain unanswered, leaving experts to wonder whether these medications truly benefit those they aim to help.
In an effort to shed light on the impact of puberty blockers on young people with gender incongruence, two new clinical trials have been announced by researchers in the UK. The moves come amid controversy over the use of these medications for minors.
Originally developed to treat early onset puberty, puberty blockers are often prescribed off-label to children with gender dysphoria or incongruence. However, a 2024 review of NHS services found insufficient evidence on their effects on psychological wellbeing, cognitive development, and fertility. As a result, the NHS announced in 2023 that children receiving puberty blockers would no longer be offered routine treatment but could only access them through research studies.
The two new trials, part of the "Pathways" programme, aim to explore the impact of these medications among young people being treated by specialist NHS services. The first study, called Pathways Trial, will recruit 226 participants aged 10-15 and randomly assign them to start puberty blockers immediately or delay treatment for a year. Participants' health and development will be closely monitored over 24 months.
Meanwhile, the second study, Pathways Connect, will involve about 250 young people β including those receiving puberty blockers and those not β undergoing MRI brain imaging and cognitive tests. The trial is expected to run for at least four years, generating significant uncertainty around the outcomes.
Critics argue that these trials are coercive in nature, as participants will be forced to wait a year before accessing treatment. Chay Brown, health director of TransActual, described this practice as "distressing" and warned it may lead to negative consequences for young trans people in the UK.
Despite concerns, researchers believe new medications often require clinical trials to assess their safety and efficacy. Emily Simonoff, professor of child and adolescent psychiatry at King's College London, acknowledged that puberty blockers were not initially tested on minors but suggested a trial was necessary given the medication's limited history.
The trials' outcomes will shed light on the long-term effects of puberty blockers on young people with gender incongruence. However, many questions remain unanswered, leaving experts to wonder whether these medications truly benefit those they aim to help.